APYXHealthcare · Medical DevicesThe 6 Wall Street analysts covering Apyx Medical Corp. hold a median 12-month price target of $6 — +154.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Apyx Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (86): Sales and profits are climbing, and climbing faster than before.
Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on APYX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +154.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Maxim Group | Initiates | Buy | $6.00 |
| 13 July 2026 | HC Wainwright & Co. | Initiates | Buy | $7.00 |
| 13 July 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 11 Mar 2026 | BTIG | Upgrade | Buy | — |
| 11 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 16 Dec 2025 | Roth Capital | Initiates | Buy | — |
| 12 Nov 2025 | Citizens | Upgrade | Market Outperform | — |
| 17 Oct 2024 | BTIG | Initiates | Neutral | — |
| 16 Sept 2024 | JMP Securities | Reiterates | Market Perform | — |
| 10 Nov 2023 | Stephens & Co. | Maintains | Overweight | — |
| 11 Aug 2023 | Piper Sandler | Maintains | Overweight | — |
| 14 July 2023 | Stephens & Co. | Initiates | Overweight | — |
| 15 June 2023 | Lake Street | Maintains | Buy | — |
| 24 May 2023 | JMP Securities | Reiterates | Market Perform | — |
| 12 May 2023 | Lake Street | Maintains | Buy | — |
| 8 Dec 2022 | Lake Street | Assumes | Buy | $5.00 |
| 12 Aug 2022 | Piper Sandler | Maintains | Overweight | — |
| 19 July 2022 | Lake Street | Maintains | Buy | — |
| 20 May 2022 | Lake Street | Initiates | Buy | — |
| 13 Aug 2021 | JMP Securities | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APYX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Apyx Medical Corp. returned −17.8% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 54% of US stocks
Cheaper than 9% of US stocks
Cheaper than 94% of US stocks
Higher than 71% of US stocks
Higher than 60% of US stocks
Higher than 77% of US stocks
Higher than 23% of US stocks
Higher than 17% of US stocks
Higher than 14% of US stocks
Higher than 34% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Apyx Medical Corp. has a market value of $107.4M and an enterprise value of $119.6M.
Revenue in the twelve months to 30 June 2026: $58.4M. The latest quarter grew 22.1% year on year.
Net income over the same four quarters: −$8.4M, a −14.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.20.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Trailing P/E: −9.4×; forward P/E: −10.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Apyx Medical Corp. employs 205 people — $285K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Apyx Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Apyx Medical announced results from a prospective clinical study evaluating the effects of its Renuvion helium plasma radiofrequency technology on biological markers of skin quality.
Why it matters — The study results provide new clinical data supporting the efficacy of Renuvion, a core product in Apyx's surgical aesthetics portfolio.
Apyx Medical is positioning its Renuvion technology and newly launched AYON Body Contouring System to serve growing demand for surgical aesthetic procedures. CEO Charlie Goodwin said this demand has been reshaped by the increasing use of GLP-1 weight-loss drugs.
Why it matters — Apyx watchers would care because the company is framing its aesthetic-device lineup as a beneficiary of the GLP-1 weight-loss trend driving demand for body-contouring procedures.
Seeking Alpha published the Q2 2026 earnings call transcript for Apyx Medical Corporation (APYX). The transcript covers the company's second-quarter 2026 earnings discussion with investors.
Why it matters — APYX watchers can review management's own commentary on the company's Q2 2026 results directly from the earnings call.
Apyx Medical reported a Q2 loss of $0.07 per share, which came in wider than the Zacks Consensus Estimate of a $0.06 loss, though narrower than the $0.09 per-share loss a year earlier. The company beat revenue estimates for the quarter.
Why it matters — For APYX watchers, the quarter shows the company's bottom-line loss improved year over year while still coming in slightly worse than analyst expectations, offering a read on its earnings trajectory.
Apyx Medical reported second-quarter revenue growth of 22% on its quarterly earnings call. The increase was driven by its surgical aesthetics business, boosted by adoption of the AYON Body Contouring System, international generator sales, and domestic demand for single-use handpieces.
Why it matters — APYX watchers would note the 22% revenue growth and the drivers cited for the company's recent performance.
The 6 Wall Street analysts covering Apyx Medical Corp. have a median 12-month price target of $6, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Apyx Medical Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apyx Medical Corp. 65 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Apyx Medical Corp. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +154.2% from the last close, and Ticker Nerd's factor model ranks Apyx Medical Corp. 65 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Apyx Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.
Apyx Medical Corp. returned -17.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures.
The most recent item we track (GlobeNewsWire, 29 Sept 2026): "Apyx Medical Announces New Clinical Study Demonstrating Renuvion®'s Impact on Skin Quality". Apyx Medical announced results from a prospective clinical study evaluating the effects of its Renuvion helium plasma radiofrequency technology on biological markers of skin quality.
Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures. Its products are used by physicians, surgery centers, hospitals, and other healthcare providers across surgical aesthetics and broader electrosurgical applications. Apyx Medical Corporation also serves original equipment manufacturing customers with engineered medical devices and components. Headquartered in Clearwater, Florida, Apyx Medical Corporation focuses on tools that combine energy delivery and surgical performance for modern operating environments.
CEO Mr. Charles D. Goodwin II · 205 employees · United States · https://apyxmedical.com
